Biomarin Pharmaceutical INC.

Based in CA

🤖

AI Overview

With $9.6M in lobbying spend across 32 quarterly filings, Biomarin Pharmaceutical INC is one of the biggest lobbying spenders in Washington. Their lobbying covers 7 issue areas. Active from 2018 to 2025.

$9.6M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$820K
2019	$1.1M
2020	$1.4M
2021	$1.0M
2022	$1.4M
2023	$1.3M
2024	$1.3M
2025	$1.3M

Issues Lobbied

Health Issues Medicare/Medicaid Trade Immigration Budget/Appropriations Taxation Tariffs

Lobbying Firms

Biomarin Pharmaceutical INC.

Lobbyists

John Greissing Kathryn Lowell Tericke Blanchard

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Trade, Immigration, Budget/Appropriations and 2 more

•H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL
•S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MAT

•GENERAL DISCUSSIONS REGARDING MEDICAID OUT OF STATE PROVIDERS, MEDICAID 1115 WAIVERS AND PRIOR AUTHORIZATION AND MEDICARE PART B AND D COVERAGE OF RARE DISEASE THERAPIES

•H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL
•H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RAR

•H.R. 6801: RARE DISEASE FUND (RaD) ACT OF 2018; ALL PROVISION OF THE BILL
•GENERAL DISCUSSIONS REGARDING GENE THERAPY
•GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH
•GENERA

•H.R. 3325: ACE KIDS ACT; ALL PROVISIONS OF THE BILL
•H.R. 6505: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2018; ALL PROVISIONS OF THE BILL
•H.R. 6524: ACCELERATING KIDS' ACCESS TO CARE ACT